Strategic Partnership Opportunity: Bochéry & Dallah Healthcare

[Virtual Presenter] Strategic Partnership Opportunity: Bochéry & Dallah Healthcare. Introducing LYTONIC Plus & Gel, Wound Care Plaster, and Gluco Sensor 24h to the K-S-A Market..

[Virtual Presenter] Index. Index. Index.

[Virtual Presenter] Objective: Our objective is to establish a strategic partnership between Bochéry and Dallah Healthcare in order to introduce innovative healthcare solutions in the Kingdom of Saudi Arabia (K-S-A--). By leveraging Dallah's strong presence in the market and Bochéry's cutting edge solutions, we aim to address the unmet needs in diabetic foot ulcer (D-F-U--) care and diabetes monitoring. Our ultimate goal is to collaborate with Dallah Healthcare to deliver groundbreaking solutions for diabetic care in the K-S-A market, utilizing Dallah's local expertise and Bochéry's advanced healthcare products..

[Audio] The population of Saudi Arabia is estimated to be approximately 34 million people as of 2024. This number has been consistently growing due to factors such as better healthcare, a younger population, and an increase in expatriate workers attracted by the expanding economic opportunities under Saudi Vision 2030. This information was provided by the General Authority for Statistics and reported by the Saudi Press Agency..

[Audio] Projected Healthcare Expenses for Diabetic Foot in Saudi Arabia Annual Cost of Treatment per Patient: Varies from SAR 40000 to SAR 80000. * Total Annual Cost for All Patients: 1 For 918000 patients: Roughly SAR 55 billion. 2 For 1530000 patients: Roughly SAR 91.8 billion. 3 For an average of 1244000 patients: Approximately SAR 73.4 billion..

[Audio] There are several factors that contribute to the high costs associated with treating ulcers and infections. First, specialized medical teams are often necessary to properly address these conditions. Additionally, advanced surgeries may be required, including amputations in severe cases. Expensive medical equipment, such as prosthetics and physiotherapy tools, also contribute to the overall cost. Furthermore, the severity of these conditions often leads to extended hospital stays, which can significantly drive up the expenses. Lastly, chronic complications, such as systemic infections, can further increase healthcare costs..

[Audio] The significance of prevention Health awareness programs: To educate the public and individuals at risk. Improved foot care for diabetic patients: Ensuring better management and monitoring. Early detection and management of mild cases: Preventing the disease from getting worse..

[Audio] The Number of Medical Centers and Hospitals Providing Diabetic Foot Care in Saudi Arabia The number of hospitals and medical centers offering treatment and care for diabetic foot patients in Saudi Arabia is increasing due to the rising prevalence of diabetes and related complications. Based on healthcare statistics and reports, here is the breakdown of relevant facilities: Number of Hospitals: *1. Hospitals: There are approximately 500 government and private hospitals in Saudi Arabia (according to data from the Ministry of Health and 2024 reports). Many of these hospitals provide specialized services for diabetic foot care. 2. Specialized Diabetes Centers: More than 50 specialized centers focus on treating and managing diabetes and diabetic foot, managed by the Ministry of Health or the private sector. 3. Specialized Units within Hospitals: Many hospitals have dedicated units or departments for diabetic foot care, particularly major hospitals such as National Guard hospitals, King Faisal Specialist Hospital, Dallah Hospital, and Dr. Sulaiman Al Habib Hospital. 4. Outpatient Clinics: Hundreds of outpatient clinics offer diabetic foot care services, including primary healthcare centers under the Ministry of Health. Notable Facilities in this Field: 1. King Faisal Specialist Hospital & Research Center 2. National Guard Health Affairs Hospitals 3. Dallah Hospital Group 4. Dr. Sulaiman Al Habib Hospitals 5. Diabetes Centers affiliated with the Ministry of Health across various regions (2261 centers) Additionally, there are 2261 primary healthcare centers affiliated with the Saudi Ministry of Health, according to recent statistics. These centers are spread throughout the Kingdom and provide comprehensive healthcare services, including preventive, curative, and promotional care..

[Audio] Ulceras en el pie diabético (D-F-U-) y amputación en Arabia Saudita: análisis de riesgos, tasas de amputación y prevalencia futura (2024-2029)..

[Audio] The Risks of Diabetic Foot Ulcers (DFUs): D-F-U Prevalence: 15-25% of people with diabetes will develop D-F-U's at some point in their lives. Main Risk Factors: Neuropathy (loss of feeling in the feet), poorly managed blood sugar levels, peripheral arterial disease, and a history of previous foot ulcers. Impact on Mortality: Patients with D-F-U's have a mortality rate of 18.5%, which is almost twice as high as those without D-F-U-s-. Amputations due to D-F-U's result in even higher mortality rates (32.2%)..

[Audio] Cases d'amputation en Arabie Saoudite Taux annuels d'amputation : 5 à 15 % des patients diabétiques avec des ulcères du pied diabétique (D-F-U--) peuvent nécessiter une amputation. Plus de 3000 amputations liées au diabète surviennent chaque année. Impact du genre : Les taux d'amputation et de mortalité sont considérablement plus élevés chez les hommes (76 à 78 %)..

[Audio] Prevalence and Forecast for the Next 5 Years For the year 2024, it is estimated that there will be approximately 6.5 million individuals with diabetes in Saudi Arabia. The rates of diabetic foot ulcers (D-F-U) are also expected to increase accordingly. Looking ahead to 2029, it is forecasted that the prevalence of diabetes in Saudi Arabia will rise to 8 million. Furthermore, it is estimated that there will be a 20% increase in amputations due to the country's population growth and aging..

[Audio] References Source 1: Saudi Health Council, Annual Diabetes Reports (2024). Source 2: W-H-O Global Diabetes Data (2023). Source 3: International Journal of Diabetes Research (2024)..

[Audio] The pharmaceutical market in Saudi Arabia is a significant industry that plays a crucial role in the healthcare sector. One of the main focus areas of this market is the treatment of diabetes, which is a prevalent health condition in the country. To gain a better understanding of the market, an analysis of its current value and the various treatments available for diabetes is necessary..

[Audio] The current value of the pharmaceutical market in Saudi Arabia is SAR 44 billion (equivalent to USD 11.72 billion) in 2022. It is projected to increase to SAR 56.6 billion (equivalent to USD 15.09 billion) by 2027. This represents a Compound Annual Growth Rate (C-A-G-R-) of 5.2%..

[Audio] Companies and Treatments Companies: Jamjoom Pharma, Avalon Pharma, Tabuk Pharmaceuticals, SPIMACO (Saudi Pharmaceutical Industries).

[Audio] Key players in the K-S-A market are important competitors in various categories, such as: D-F-U Care, which includes Johnson & Johnson, Smith & Nephew, and Mölnlycke Health Care C-G-M-S-, which includes Abbott (Freestyle Libre), Medtronic (Guardian), and Dexcom Wound Care Plasters, which includes 3M Healthcare, Smith & Nephew, and regional distributors..

[Audio] Market Opportunity in K-S-A A Diabetes in Saudi Arabia: There are 7 million people in Saudi Arabia affected by diabetes, and this number is expected to rise. There is a growing demand for D-F-U solutions and real time glucose monitoring technology. B Key Market Segments for Each Product: 1. LYTONIC Plus & Gel for D-F-U--: The market for this product is 450 million Saudi Arabian Riyals, with an expected annual growth of 10%. 2. Wound Care Plaster for D-F-U--: The market for this product is 200 million Saudi Arabian Riyals, and there is an increasing demand for non invasive solutions. 3. Gluco Sensor 24h C-G-M-S-: The market for this product is 500 million Saudi Arabian Riyals, and there is a significant growth potential due to the heightened demand for diabetes management technology..

[Audio] Initial Investment & Partnership Setup For each product line, there is a need for a strategic investment, which includes obtaining regulatory approvals and implementing marketing strategies. The initial investment required for LYTONIC is 1.5 million dollars (equivalent to 5.6 million Saudi Arabian Riyals). The initial investment needed for Wound Care Plaster is 1 million dollars (equivalent to 3.75 million Saudi Arabian Riyals). The initial investment for Gluco Sensor 24h is 2 million dollars (equivalent to 7.5 million Saudi Arabian Riyals). Please note that partnering with Dallah will assist in fulfilling local regulatory requirements and establishing a distribution network..

[Audio] Initial Investment & Partnership Setup Initial Investment / million S-A-R LYTONIC Gel & Cap. Wound Care Plaster Gluco Sensor 24h C-G-M-S G T 5.6 3.75 7.5 16.85 Product: Initial Investment / million S-A-R LYTONIC Gel & Cap. S-A-R 5.60 Wound Care Plaster S-A-R 3.75 Gluco Sensor 24h CGMS SAR 7.50 G T Sar 16.85.

[Audio] Projected Financials for Each Product (5 Years) LYTONIC: Anticipated yearly revenue of SAR 20 million; net profit of 25%. Wound Care Plaster: Anticipated yearly revenue of SAR 11 million; net profit of 20%. Gluco Sensor 24h: Anticipated yearly revenue of SAR 26 million; net profit of 30%..

[Audio] The Payback Period Analysis shows the amount of time it will take for each product investment to make a return on its initial cost. The estimated payback period for LYTONIC is 3 years, for Wound Care Plaster it is 3.5 years, and for Gluco Sensor 24h it is 2.5 years..

[Audio] The overview of project finances (combined): Combined revenue and profitability: Total estimated revenue after 5 years: 75 million dollars Total net profit: 25% on combined investment Cumulative payback period for all products: Approximately 3 years..

[Audio] Projected financials for each product for the next 5 years and analysis of payback period. Expected revenue in million Saudi riyals (S-A-R--) per year: LYTONIC Gel & Cap.: 20 million S-A-R Wound Care Plaster: 11 million S-A-R Gluco Sensor 24h CGMS: 26 million S-A-R G T: 57 million S-A-R PRODUCT Expected Revenue (S-A-R--) million SAR/Year Net Profit (%) Payback period LYTONIC Gel & Cap. SAR 20.00 25% 3.00 Wound Care Plaster SAR 11.00 20% 3.50 Gluco Sensor 24h CGMS SAR 26.00 30% 2.50 G T Sar 57.00 25% 3.00.

[Audio] Slide for Conclusion and Next Steps Highlight the mutual benefits of the partnership and outline the next steps for launching in K-S-A. These steps include approval of partnership terms, completing regulatory filings, and conducting product trials specific to the market. Additionally, joint marketing campaigns will be deployed and distribution channels will be established through Dallah's healthcare network..

[Audio] Calculation: We need to determine our target for serving D-F-U (Diabetic Foot Ulcers) patients. In Saudi Arabia, there are 11 cases of limb amputation due to diabetes every day. Our target is to reduce this number by 50%. According to the latest statistics, there are approximately 4000000 cases of diabetes in Saudi Arabia, which would result in 1000000 D-F-U cases. Our annual target is to serve 100006 D-F-U patients, which is 10% of the expected D-F-U cases in the country..

[Audio] Calculation for cost component and estimated profit margin for D-F-U patients: LYTONIC Plus 60 Cap. Dosage: Twice daily, 2 packs per month, 24 packs per year at SAR 500.00 per pack. LYTONIC Gel Dosage: Twice daily, 8 packs per month, 96 packs per year at SAR 300.00 per pack. Wound Care products Dosage: Twice daily, 60720 packs per year at SAR 200.00 per pack. Cost forecast for one D-F-U patient (per year): LYTONIC Plus 60 Cap. Dosage: SAR 24000 LYTONIC Gel Dosage: SAR 28800 Wound Care products Dosage: SAR 12144000 Total cost forecast: SAR 12196800 Target profit from the total D-F-U patients (1000000 patients): 1% of 1000000 patients = 10000 patients Cost forecast for target D-F-U patients (per year): LYTONIC Plus 60 Cap. Dosage: SAR 240000000 LYTONIC Gel Dosage: SAR 288000000 Wound Care products Dosage: SAR 121440000000 Total cost forecast: SAR 121968000000 Estimated profit margin (20%): Sar 121,968,000,000 X 20% = Sar 24,393,600,000 Therefore, the estimated profit margin for D-F-U patients is SAR 24393600000..

[Audio] Bochéry & Dallah Healthcare: A Strategic Alliance for the Future of Diabetic Care in Saudi Arabia.